

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-15. (Canceled)

16. (Previously Presented) A method for treating rheumatoid arthritis in a human subject, said method comprising administering to said subject a therapeutically effective amount of an IL-12 antagonist that binds with IL-12, wherein said antagonist is chosen from a group consisting of an antibody immunoreactive with IL-12 and an antibody fragment immunoreactive with IL-12.

17. (Canceled)

18. (Previously Presented) The method of claim 16, wherein said antagonist is administered in combination with a pharmaceutically acceptable carrier.

19. (Previously Presented) The method of claim 16, wherein said antagonist is an antibody immunoreactive with IL-12.

20. (Previously Presented) The method of claim 16, wherein said antagonist is an antibody fragment is immunoreactive with IL-12.

21. (Previously Presented) The method of claim 16, wherein the antibody is a monoclonal antibody.

22. (Previously Presented) The method of claim 16, wherein the antibody binds to a heterodimer comprised of a 40 kD subunit and an 35 kD subunit of IL-12.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- 23. (Canceled)
- 24. (Canceled)
- 25. (Previously Presented) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.05 to about 25 mg/kg.
- 26. (Previously Presented) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.2 to about 2 mg/kg.
- 27. (Previously Presented) The method of claim 16, wherein said antagonist is administered intravenously.
- 28. (Previously Presented) The method of claim 16, wherein said antagonist is administered subcutaneously.
- 29. (Previously Presented) The method of claim 16, wherein said antagonist is administered cutaneously.
- 30. (Previously Presented) The method of claim 16, wherein said antagonist is administered in combination with other therapies for autoimmune conditions.
- 31. (Previously Presented) The method of claim 30, wherein said therapies comprise steroidal or other anti-inflammatory therapies.
- 32-43. (Canceled)